Revolutionizing Gene Editing: Regeneron and Mammoth Biosciences’ $100M Partnership

1. Regeneron Pharmaceuticals and Mammoth Biosciences have announced a $100 million collaboration to develop a novel gene-editing therapy using CRISPR technology.

2. The partnership aims to combine Mammoth's proprietary CRISPR platform with Regeneron's innovative delivery system to create a more efficient and targeted gene-editing solution.

3. Mammoth Biosciences is known for its work on CRISPR-Cas systems, including the development of ultra-compact Cas proteins for gene editing.

4. Regeneron, a leading biotechnology company, brings its expertise in drug discovery and development, as well as its proprietary delivery technology, to the collaboration.

5. The partnership is expected to accelerate the development of new gene-editing therapies for a range of diseases, potentially revolutionizing the field of healthcare and medicine.

6. The deal includes an upfront payment, an equity investment, and potential milestone payments and royalties, totaling up to $100 million.

7. This collaboration is a significant step towards overcoming the challenges of delivering CRISPR therapies to specific cells and tissues in the body.

8. The partnership between Regeneron and Mammoth Biosciences is a testament to the growing interest and investment in gene-editing technologies and their potential to transform healthcare.